RegenXBio Inc. (RGNX)
NASDAQ:RGNX
Want to see RGNX full AI Analyst Report?
RGNX Stock Chart & Stats
$9.49
-$0.26(-3.11%)
At close: 4:00 PM EST
$9.49
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.46 - $16.19
Previous CloseN/A
Volume155.59K
Average Volume (3M)1.26M
Market Cap
$292.09M
Enterprise Value$364.47M
Total Cash (Recent Filing)$150.49M
Total Debt (Recent Filing)$71.07M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Aug 05, 2026EPS Estimate
0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.60
Shares Outstanding51,697,620
10 Day Avg. Volume2,643,205
30 Day Avg. Volume1,263,170
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue4.15
Enterprise Value/Gross Profit-3.04K
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$22.78Price Target Upside140.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.85
Revenue Forecast (FY)$234.86M
Bulls Say, Bears Say
Bulls Say
Financial Runway And Partner SupportSolid cash resources, committed partner funding and stronger-than-expected licensing and royalty revenue could extend the development runway and lower near-term financing risk.
Manufacturing And Regulatory AlignmentCommercial-scale manufacturing of RGX-202 and plans to seek pre-submission alignment with regulators reduce execution risk around a potential regulatory filing and commercial launch.
Pivotal Trial ReadoutsTopline pivotal readouts for the Duchenne RGX-202 program and late-stage sura-vec retinal studies could enable regulatory filings and meaningful commercial opportunities if efficacy and safety are confirmed.
Bears Say
Clinical Variability And Limited Sample SizeSubstantial variability in patient responses and small early sample sizes increase uncertainty about treatment effectiveness and make it harder to build conviction ahead of pivotal trials.
Regulatory Uncertainty From Agency FeedbackA complete response letter highlighting uncertainty in target population definition, control comparability and surrogate endpoint relevance has created a regulatory overhang and complicates approval pathways.
Safety Findings And Clinical HoldsDetection of a brain tumor in a related program and evidence of viral vector integration near cancer-related genes prompted clinical holds, creating material safety uncertainty for linked programs.
RegenXBio News
RGNX FAQ
What was RegenXBio Inc.’s price range in the past 12 months?
RegenXBio Inc. lowest stock price was $5.46 and its highest was $16.19 in the past 12 months.
What is RegenXBio Inc.’s market cap?
RegenXBio Inc.’s market cap is $292.09M.
When is RegenXBio Inc.’s upcoming earnings report date?
RegenXBio Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 76 days.
How were RegenXBio Inc.’s earnings last quarter?
RegenXBio Inc. released its earnings results on May 14, 2026. The company reported -$1.72 earnings per share for the quarter, missing the consensus estimate of -$1.337 by -$0.383.
Is RegenXBio Inc. overvalued?
According to Wall Street analysts RegenXBio Inc.’s price is currently Undervalued.
Does RegenXBio Inc. pay dividends?
RegenXBio Inc. does not currently pay dividends.
What is RegenXBio Inc.’s EPS estimate?
RegenXBio Inc.’s EPS estimate is 0.25.
How many shares outstanding does RegenXBio Inc. have?
RegenXBio Inc. has 51,697,620 shares outstanding.
What happened to RegenXBio Inc.’s price movement after its last earnings report?
RegenXBio Inc. reported an EPS of -$1.72 in its last earnings report, missing expectations of -$1.337. Following the earnings report the stock price went down -37.799%.
Which hedge fund is a major shareholder of RegenXBio Inc.?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.78 (140.02% Upside)
$22.78 (140.02% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 162.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Bullish
Bullish news 79%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.30%
12-Months-Change
Fundamentals
Return on Equity
-232.50%
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
RegenXBio Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a notably positive clinical and programmatic update: RGX-202 met its pivotal primary endpoint with high biomarker expression, demonstrated an unusually strong correlation between microdystrophin and functional benefit (>0.9), and showed encouraging interim safety and functional signals with plans for potential accelerated approval in 2027. Key operational and regulatory risks were acknowledged — chiefly the limited number of mature 12‑month functional datapoints so far, reliance on external controls (and FDA concern about bias), and the possibility that the agency could request randomized trials which would materially delay approval. Remaining uncertainties on long‑term durability and the logistical burden of the prophylaxis regimen were also discussed. Overall the clinical readout and pipeline progress meaningfully outweigh near‑term risks, but regulatory process and more mature datasets remain critical next milestones.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$22.78
▲(140.02% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
8.74% Insiders
17.47% Mutual Funds
20.55% Other Institutional Investors
37.88% Public Companies and
Individual Investors